ENTYVIO (also known as Vedolizumab)

Mechanism:

Entyvio is an antibody that binds to a gut-specific cell adhesion molecule / integrin and thereby reduces gut-specific inflammation.

Indications:

• Adults with active, moderate-to-severe Ulcerative Colitis who did not respond or could not tolerate a TNF blocker like Remicade OR who did not respond or could not tolerate or became dependent on steroids.
• Adults with active, moderate-to-severe Crohn’s Disease who did not respond or could not tolerate a TNF blocker like Remicade OR who did not respond or could not tolerate or became dependent on steroids.

Contraindications:

Patients with active infection should not be started on Entyvio.

Administration:

Entyvio is typically administered as an infusion over thirty minutes and repeated at week 2, 6, and every 8 weeks thereafter.